title: Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model.
abstract: Epitope vaccine is a promising option for therapeutic vaccination against Helicobacter pylori (H. pylori) infection. In this study, we constructed a multi-epitope vaccine with five epitopes and mucosal adjuvant E. coli heat-labile enterotoxin B subunit (LTB) named HUepi-LTB and evaluated its therapeutic effect against H. pylori infection in BALB/c mice model. HUepi-LTB containing three Th epitopes from UreB and two B cell epitopes from UreB and HpaA was constructed and expressed in E. coli. Oral therapeutic immunization with HUepi-LTB significantly decreased H. pylori colonization compared with oral immunization with PBS, and the protection was correlated with antigen-specific CD4+ T cells and IgG and mucosal IgA antibody responses. This multi-epitope vaccine may be a promising vaccine candidate that may help to control H. pylori infection.
authors.affiliation: Department of Clinical Microbiology and Immunology, College of Medical Laboratory Science, The Third Military Medical University, Chongqing 400038, PR China.
authors.forename: Wei-Ying
authors.initials: WY
authors.lastname: Zhou
authors.forename: Yun
authors.initials: Y
authors.lastname: Shi
authors.forename: Chao
authors.initials: C
authors.lastname: Wu
authors.forename: Wei-Jun
authors.initials: WJ
authors.lastname: Zhang
authors.forename: Xu-Hu
authors.initials: XH
authors.lastname: Mao
authors.forename: Gang
authors.initials: G
authors.lastname: Guo
authors.forename: Hai-Xia
authors.initials: HX
authors.lastname: Li
authors.forename: Quan-Ming
authors.initials: QM
authors.lastname: Zou
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000494:pharmacology; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004768:Enterotoxins / Q000008:administration & dosage / Q000494:pharmacology; D018985:Epitopes, B-Lymphocyte / Q000235:genetics / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology*; D004926:Escherichia coli / Q000235:genetics; D029968:Escherichia coli Proteins / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D016481:Helicobacter Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D016480:Helicobacter pylori / Q000235:genetics / Q000276:immunology*; D006801:Humans; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D004768:Enterotoxins; D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D029968:Escherichia coli Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D014614:Vaccines, Synthetic; C027538:heat-labile enterotoxin, E coli